Modafinil for the treatment of cocaine dependence

Ann L. Anderson, Malcolm S. Reid, Shou Hua Li, Tyson Holmes, Lynn Shemanski, April Slee, Edwina V. Smith, Roberta Kahn, Nora Chiang, Frank Vocci, Domenic Ciraulo, Charles Dackis, John D. Roache, Ihsan M Salloum, Eugene Somoza, Harold C. Urschel, Ahmed M. Elkashef

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Aim: Modafinil was tested for efficacy in facilitating abstinence in cocaine-dependent patients, compared to placebo. Methods: This was a double-blind placebo-controlled study, with 12 weeks of treatment and a 4-week follow-up. Six outpatient substance abuse treatment clinics participated in the study. There were 210 treatment-seekers randomized, having a diagnosis of cocaine dependence; 72 participants were randomized to placebo, 69 to modafinil 200 mg, and 69 to modafinil 400 mg, taken once daily on awakening. Participants came to the clinic three times per week for assessments and urine drug screens, and had one hour of individual psychotherapy weekly. The primary outcome measure was the weekly percentage of cocaine non-use days. Results: The GEE regression analysis showed that for the total sample, there was no significant difference between either modafinil group and placebo in the change in average weekly percent of cocaine non-use days over the 12-week treatment period (p > 0.79). However, two secondary outcomes showed significant effects by modafinil 200 mg: the maximum number of consecutive non-use days for cocaine (p = 0.02), and a reduction in craving (p = 0.04). Also, a post hoc analysis showed a significant effect of modafinil that increased the weekly percentage of non-use days in the subgroup of those cocaine patients who did not have a history of alcohol dependence (p < 0.02). Conclusions: These data suggest that modafinil, in combination with individual behavioral therapy, was effective for increasing cocaine non-use days in participants without co-morbid alcohol dependence, and in reducing cocaine craving.

Original languageEnglish
Pages (from-to)133-139
Number of pages7
JournalDrug and Alcohol Dependence
Volume104
Issue number1-2
DOIs
StatePublished - Sep 1 2009

Fingerprint

Cocaine-Related Disorders
Cocaine
Placebos
Therapeutics
Alcoholism
Alcohols
modafinil
Psychotherapy
Substance-Related Disorders
Regression analysis
Outpatients
Regression Analysis
Outcome Assessment (Health Care)
Urine
Pharmaceutical Preparations

Keywords

  • Alcoholism
  • Cocaine-related disorders
  • Modafinil
  • Pharmacotherapy
  • Risk factors

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Anderson, A. L., Reid, M. S., Li, S. H., Holmes, T., Shemanski, L., Slee, A., ... Elkashef, A. M. (2009). Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence, 104(1-2), 133-139. https://doi.org/10.1016/j.drugalcdep.2009.04.015

Modafinil for the treatment of cocaine dependence. / Anderson, Ann L.; Reid, Malcolm S.; Li, Shou Hua; Holmes, Tyson; Shemanski, Lynn; Slee, April; Smith, Edwina V.; Kahn, Roberta; Chiang, Nora; Vocci, Frank; Ciraulo, Domenic; Dackis, Charles; Roache, John D.; Salloum, Ihsan M; Somoza, Eugene; Urschel, Harold C.; Elkashef, Ahmed M.

In: Drug and Alcohol Dependence, Vol. 104, No. 1-2, 01.09.2009, p. 133-139.

Research output: Contribution to journalArticle

Anderson, AL, Reid, MS, Li, SH, Holmes, T, Shemanski, L, Slee, A, Smith, EV, Kahn, R, Chiang, N, Vocci, F, Ciraulo, D, Dackis, C, Roache, JD, Salloum, IM, Somoza, E, Urschel, HC & Elkashef, AM 2009, 'Modafinil for the treatment of cocaine dependence', Drug and Alcohol Dependence, vol. 104, no. 1-2, pp. 133-139. https://doi.org/10.1016/j.drugalcdep.2009.04.015
Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A et al. Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence. 2009 Sep 1;104(1-2):133-139. https://doi.org/10.1016/j.drugalcdep.2009.04.015
Anderson, Ann L. ; Reid, Malcolm S. ; Li, Shou Hua ; Holmes, Tyson ; Shemanski, Lynn ; Slee, April ; Smith, Edwina V. ; Kahn, Roberta ; Chiang, Nora ; Vocci, Frank ; Ciraulo, Domenic ; Dackis, Charles ; Roache, John D. ; Salloum, Ihsan M ; Somoza, Eugene ; Urschel, Harold C. ; Elkashef, Ahmed M. / Modafinil for the treatment of cocaine dependence. In: Drug and Alcohol Dependence. 2009 ; Vol. 104, No. 1-2. pp. 133-139.
@article{fe8349e18cdb4882b60b4a27adedf92f,
title = "Modafinil for the treatment of cocaine dependence",
abstract = "Aim: Modafinil was tested for efficacy in facilitating abstinence in cocaine-dependent patients, compared to placebo. Methods: This was a double-blind placebo-controlled study, with 12 weeks of treatment and a 4-week follow-up. Six outpatient substance abuse treatment clinics participated in the study. There were 210 treatment-seekers randomized, having a diagnosis of cocaine dependence; 72 participants were randomized to placebo, 69 to modafinil 200 mg, and 69 to modafinil 400 mg, taken once daily on awakening. Participants came to the clinic three times per week for assessments and urine drug screens, and had one hour of individual psychotherapy weekly. The primary outcome measure was the weekly percentage of cocaine non-use days. Results: The GEE regression analysis showed that for the total sample, there was no significant difference between either modafinil group and placebo in the change in average weekly percent of cocaine non-use days over the 12-week treatment period (p > 0.79). However, two secondary outcomes showed significant effects by modafinil 200 mg: the maximum number of consecutive non-use days for cocaine (p = 0.02), and a reduction in craving (p = 0.04). Also, a post hoc analysis showed a significant effect of modafinil that increased the weekly percentage of non-use days in the subgroup of those cocaine patients who did not have a history of alcohol dependence (p < 0.02). Conclusions: These data suggest that modafinil, in combination with individual behavioral therapy, was effective for increasing cocaine non-use days in participants without co-morbid alcohol dependence, and in reducing cocaine craving.",
keywords = "Alcoholism, Cocaine-related disorders, Modafinil, Pharmacotherapy, Risk factors",
author = "Anderson, {Ann L.} and Reid, {Malcolm S.} and Li, {Shou Hua} and Tyson Holmes and Lynn Shemanski and April Slee and Smith, {Edwina V.} and Roberta Kahn and Nora Chiang and Frank Vocci and Domenic Ciraulo and Charles Dackis and Roache, {John D.} and Salloum, {Ihsan M} and Eugene Somoza and Urschel, {Harold C.} and Elkashef, {Ahmed M.}",
year = "2009",
month = "9",
day = "1",
doi = "10.1016/j.drugalcdep.2009.04.015",
language = "English",
volume = "104",
pages = "133--139",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Modafinil for the treatment of cocaine dependence

AU - Anderson, Ann L.

AU - Reid, Malcolm S.

AU - Li, Shou Hua

AU - Holmes, Tyson

AU - Shemanski, Lynn

AU - Slee, April

AU - Smith, Edwina V.

AU - Kahn, Roberta

AU - Chiang, Nora

AU - Vocci, Frank

AU - Ciraulo, Domenic

AU - Dackis, Charles

AU - Roache, John D.

AU - Salloum, Ihsan M

AU - Somoza, Eugene

AU - Urschel, Harold C.

AU - Elkashef, Ahmed M.

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Aim: Modafinil was tested for efficacy in facilitating abstinence in cocaine-dependent patients, compared to placebo. Methods: This was a double-blind placebo-controlled study, with 12 weeks of treatment and a 4-week follow-up. Six outpatient substance abuse treatment clinics participated in the study. There were 210 treatment-seekers randomized, having a diagnosis of cocaine dependence; 72 participants were randomized to placebo, 69 to modafinil 200 mg, and 69 to modafinil 400 mg, taken once daily on awakening. Participants came to the clinic three times per week for assessments and urine drug screens, and had one hour of individual psychotherapy weekly. The primary outcome measure was the weekly percentage of cocaine non-use days. Results: The GEE regression analysis showed that for the total sample, there was no significant difference between either modafinil group and placebo in the change in average weekly percent of cocaine non-use days over the 12-week treatment period (p > 0.79). However, two secondary outcomes showed significant effects by modafinil 200 mg: the maximum number of consecutive non-use days for cocaine (p = 0.02), and a reduction in craving (p = 0.04). Also, a post hoc analysis showed a significant effect of modafinil that increased the weekly percentage of non-use days in the subgroup of those cocaine patients who did not have a history of alcohol dependence (p < 0.02). Conclusions: These data suggest that modafinil, in combination with individual behavioral therapy, was effective for increasing cocaine non-use days in participants without co-morbid alcohol dependence, and in reducing cocaine craving.

AB - Aim: Modafinil was tested for efficacy in facilitating abstinence in cocaine-dependent patients, compared to placebo. Methods: This was a double-blind placebo-controlled study, with 12 weeks of treatment and a 4-week follow-up. Six outpatient substance abuse treatment clinics participated in the study. There were 210 treatment-seekers randomized, having a diagnosis of cocaine dependence; 72 participants were randomized to placebo, 69 to modafinil 200 mg, and 69 to modafinil 400 mg, taken once daily on awakening. Participants came to the clinic three times per week for assessments and urine drug screens, and had one hour of individual psychotherapy weekly. The primary outcome measure was the weekly percentage of cocaine non-use days. Results: The GEE regression analysis showed that for the total sample, there was no significant difference between either modafinil group and placebo in the change in average weekly percent of cocaine non-use days over the 12-week treatment period (p > 0.79). However, two secondary outcomes showed significant effects by modafinil 200 mg: the maximum number of consecutive non-use days for cocaine (p = 0.02), and a reduction in craving (p = 0.04). Also, a post hoc analysis showed a significant effect of modafinil that increased the weekly percentage of non-use days in the subgroup of those cocaine patients who did not have a history of alcohol dependence (p < 0.02). Conclusions: These data suggest that modafinil, in combination with individual behavioral therapy, was effective for increasing cocaine non-use days in participants without co-morbid alcohol dependence, and in reducing cocaine craving.

KW - Alcoholism

KW - Cocaine-related disorders

KW - Modafinil

KW - Pharmacotherapy

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=67651089681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651089681&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2009.04.015

DO - 10.1016/j.drugalcdep.2009.04.015

M3 - Article

C2 - 19560290

AN - SCOPUS:67651089681

VL - 104

SP - 133

EP - 139

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1-2

ER -